V
arious challenging behavioral and psychological symptoms commonly develop in older adults with dementia and predispose them and their caregivers to poor outcomes (1) . Nonpharmacologic strategies are recommended as first-line management for these symptoms (2), but they may be difficult to implement in clinical practice (3) . For many reasons, antipsychotic medications are routinely prescribed in this setting (4, 5) . Conventional antipsychotics, such as haloperidol, have been available since the 1950s. Meta-analyses of clinical trials evaluating conventional antipsychotics to treat agitation in dementia show that these agents have modest efficacy and important adverse effects compared with placebo (6, 7) . In the past decade, use of newer "atypical" antipsychotics has been rapidly increasing in clinical practice because these agents were thought to produce fewer adverse effects than conventional agents (2) . A Canadian study found that the prevalence of antipsychotic use in older adults increased from 2.2% in 1993 to 3.0% at the end of 2002. In that study, atypical antipsychotics, which were unavailable in 1993, accounted for 82.5% of all antipsychotics dispensed in 2002 (8) . Short-term randomized, controlled trials (RCTs) have studied the role of atypical antipsychotics in the management of behavioral and psychological symptoms of dementia (2, 9 ). An RCT involving 421 outpatients with Alzheimer disease and psychosis, aggression, or agitation concluded that the adverse effects of these newer drugs offset their advantages (10) . As a result, improvements in behavioral symptoms with antipsychotic drug treatment do not necessarily lead to improvements in overall quality of life for patients or their caregivers (11) .
In April 2005, the U.S. Food and Drug Administration (FDA) issued a public health advisory that the use of atypical antipsychotics to treat elderly patients with dementia was associated with an increased risk for death compared with placebo (12) . In June 2005, Health Canada issued a similar warning and additional data (13) . These warnings stem from reviews of RCTs that involve the atypical agents risperidone, olanzapine, quetiapine, and aripiprazole. The mortality rate was approximately 1.6 to 1.7 times higher than with placebo and was greater with antipsychotics than with placebo in 15 of the 17 trials reviewed by the U.S. FDA (12) . The warnings extend to all currently available atypical antipsychotics. Other publications have provided support for these warnings and have raised further safety concerns about older conventional antipsychotics (14 -16) .
Important questions remain unanswered. Although RCTs provide the best evidence of treatment efficacy and harm, the individual RCTs in this case had low event rates. Reliable estimates of the mortality risk were generated only when data were combined by meta-analysis (14) . Furthermore, these RCTs were generally short in duration and could not provide information about the long-term effect of antipsychotics on mortality (14, 17) . Finally, these trials provide estimates of harm primarily for atypical antipsychotics. Relatively few data are available on harms associated with older conventional antipsychotics. Studies suggest that important differences may exist in the safety profiles of conventional and atypical agents (15, 16, 18, 19) .
Using population-based data, we sought to determine the risk for all-cause mortality in older adults with dementia who received atypical antipsychotics, conventional antipsychotics, or no antipsychotic. Because important baseline differences exist among these groups, we used propensity score matching to improve their comparability. We also evaluated the effect of duration of treatment with antipsychotics on the risk for death.
METHODS

Data Sources
Ontario is Canada's most populous province. During our study, Ontario had a population of approximately 12 million people, of whom 1.4 million were 65 years of age or older. A universally funded health program covers nearly all physician services, medications, and hospital services for patients 65 years of age or older in Ontario. Information from 4 administrative health care databases was linked to develop the study cohort: pharmacy records from the Ontario Drug Benefit program, hospitalization records from the Canadian Institute for Health Information Discharge Abstract Database, physician billing information for inpatient and outpatient services from the Ontario Health Insurance Plan, and basic demographic information and vital statistics from the Registered Persons Database. We used encrypted unique identifiers that are common among databases to link anonymous information on demographic characteristics and health services utilization for patients in our study. Little basic information on patients is missing in these databases. For example, the coding accuracy of drug claims in the Ontario Drug Benefit program database is excellent, with an error rate of only 0.7% (20) .
The study was approved by the ethics review board of Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada.
Dementia Cohort
We identified a cohort of all Ontario residents 66 years of age or older with a diagnosis of dementia (in the Ontario Health Insurance Plan or Discharge Abstract Database) between 1 April 1997 and 31 March 2002. To focus on antipsychotic drug treatment for behavioral and psychological symptoms of dementia, we excluded patients who had evidence of other psychotic disorders (such as schizophrenia) or were receiving palliative care services. To reduce the potential for selection bias, we studied only new users of antipsychotics and excluded those who had received antipsychotics in the year before cohort entry (21) .
Exposure to Antipsychotics
We identified new use of antipsychotics if any agent available through the Ontario Drug Benefit program was dispensed after cohort entry. Cohort entry (that is, the index date) was defined as the date of the first dispensed antipsychotic drug. Available atypical drugs included olanzapine, quetiapine, and risperidone, and available conventional drugs included chlorpromazine, flupenthixol, fluphenazine, haloperidol, loxapine, pericyazine, perphenazine, pimozide, thioridazine, and trifluoperazine. Clozapine was rarely used in Ontario during the study period, and we therefore excluded patients who were receiving this medication. Other atypical antipsychotics (such as aripiprazole and ziprasidone) are not licensed for use in Canada. We decided that exposure to an antipsychotic was discontinued (and we censored follow-up) if the patient did not refill his or her antipsychotic prescription within an interval composed of the days of drug supply plus a grace period of 20%. For example, we censored follow-up for a patient who did not refill his or her 60-day antipsychotic prescription within 72 days. We also censored follow-up for patients who switched from atypical to conventional antipsychotics (or vice versa). However, we continued follow-up for patients who switched from 1 atypical antipsychotic to another, because data suggest no statistically significant dif-ference in the risk for death associated with individual drugs in this class (13, 14, 16) . We applied the same rules to conventional antipsychotics.
All-Cause Mortality
The primary outcome was all-cause mortality, as recorded in the Registered Persons Database (for patients who were not hospitalized at the time of death) or the Discharge Abstract Database (for patients who died while hospitalized). To assess the influence of the duration of antipsychotic exposure on the outcome, we evaluated the risk for death at 30, 60, 120, and 180 days after the initial dispensing of antipsychotic medication.
Cohort Matching
We stratified the dementia cohort to support separate analyses among persons living in the community and those residing in long-term care at cohort entry. Studies have demonstrated that rates of antipsychotic prescribing are substantial among older adults newly admitted to longterm care facilities (4) . Furthermore, long-term care residents typically carry a greater burden of comorbid disease and are more vulnerable to adverse drug events than are their counterparts in the community (22, 23) .
Our first objective was to determine the risk for death among older adults with dementia who received atypical antipsychotics compared with those who were not exposed to any antipsychotic. Because antipsychotic use was not randomly assigned in the study cohorts, we addressed potential confounding and selection biases by developing a propensity score for antipsychotic use. We then applied this score to match users of atypical antipsychotics with nonusers in the dementia cohort. The rationale and methods underlying the use of a propensity score for a proposed causal exposure variable are described elsewhere (24) . Recent studies provide guidance on the selection of variables to include in the propensity score (25, 26) . We developed a logistic regression model by using 42 covariates describing patient characteristics. Tables 1 and 2 list many of the characteristics included in the propensity score. After a structured and iterative assessment of the balance of measured covariates between atypical antipsychotic users and nonusers, we applied additional forced matching to a variable indicating the presence of a hospitalization in the 90 days before cohort entry. This variable was thought to be an important predictor of new antipsychotic use and was not well balanced between groups in the propensity score. Using the resulting predicted probabilities as propensity scores, we matched each atypical antipsychotic user with a nonuser by utilizing a caliper width (that is, interval for successful match) of 0.6 of the SD of the log odds of the propensity score. This method has been demonstrated to remove approximately 90% of the bias from measured confounders (27) . These steps were completed separately for each stratum (community-dwelling older adults compared with long-term care residents), resulting in 2 groups of matched pairs.
Our second objective was to determine the risk for death with conventional antipsychotic use compared with atypical antipsychotic use. We repeated the propensity score-matching process to create matched cohorts of new users of conventional and atypical antipsychotics. We stratified analyses to examine older adults residing in the community and in long-term care separately. We developed 4 We used a "greedy matching" algorithm (available at www2.sas.com/proceedings/sugi26/p214-26.pdf) to match new users of atypical antipsychotics to nonusers and new users of conventional antipsychotics to new users of atypical antipsychotics. Atypical antipsychotic users were eligible for both comparisons. We matched only patients with an adequate match as defined earlier and sacrificed completeness of matching for accuracy of matching.
Statistical Analysis
To examine the effects of antipsychotic use on mortality, we first examined absolute risk differences in cumulative mortality rates. We estimated 95% CIs for the absolute risk differences by using bootstrap methods with matched pairs repeated 1000 times. We then conducted survival analysis by using Cox proportional hazards models on our 4 matched cohorts. To address possible residual confounding after the matching process, we performed traditional risk adjustment with covariates that strongly influence mortality (28) . The covariates in our models were age, sex, and dichotomous variables for the individual medical conditions included in the Charlson comorbidity index (acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic pulmonary disease, connective tissue disease, ulcer disease, mild liver disease, diabetes [with and without end-organ damage], hemiplegia or paraplegia, moderate or severe renal disease, primary cancer, moderate or severe liver disease, and metastatic cancer) (29). Analyses involved stratified Cox proportional hazards models using the STRATA option of the PROC PHREG procedure in SAS, version 9.1 (SAS Institute, Inc., Cary, North Carolina), to account for the matched pair design. We ran separate models for the 30-, 60-, 120-, and 180-day end points. We confirmed the proportional hazards assumption for all models by using an interaction term between the independent variable and time. Because the P value for the term was greater than 0.05 for all comparisons, we concluded that the assumption of proportional hazards was satisfied.
Although propensity score matching helps to balance groups on measured covariates, our study is observational, and unknown or unmeasured confounders may influence the results. As other investigators have done (30, 31), we conducted sensitivity analyses to investigate the potential effects of unmeasured confounders on the observed associations. Our sensitivity analyses investigated the effects of a hypothetical binary confounder on the observed hazard ratios for 2 comparisons in community-dwelling patients: the 30-day outcome for atypical antipsychotic use compared with no antipsychotic use, and the 30-day outcome for conventional antipsychotic use compared with atypical antipsychotic use. We varied the prevalence of the hypothetical unmeasured confounder in the 2 comparison groups, as well as the relative hazard of death associated with this unmeasured confounder.
Role of the Funding Source
The Canadian Institutes for Health Research funded the study. The funding source had no role in the design, conduct, or reporting of the study or in the decision to submit the manuscript for publication.
RESULTS
Matching Process and Patient Characteristics
For the comparison of atypical antipsychotic use with nonuse, we identified 9100 matched pairs of communitydwelling older adults and 4036 matched pairs of long-term care residents. For the comparison of conventional with atypical antipsychotic use, we identified 6888 matched pairs of community-dwelling older adults and 7235 matched pairs of long-term care residents. Thus, the study included data on 27 259 propensity score-matched pairs. The matching process produced excellent balance for covariates in the propensity score (Tables 1 and 2) . The standardized differences for these comparisons were nearly all less than 10%. No value was missing for demographic data or data used to construct the covariates (all analysis variables were mandatory fields in our administrative databases). In the community-dwelling cohort, atypical antipsychotic users started treatment with risperidone (75.2%), olanzapine (19.6%), and quetiapine (5.2%) and conventional antipsychotic users started treatment with haloperidol (60.2%), loxapine (17.9%), thioridazine (10.3%), chlorpromazine (5.8%), and perphenazine (3.5%). The breakdown of antipsychotic use was similar in the longterm care cohort.
In all comparisons, matches were limited by the smaller of the 2 comparison groups. In the comparison of atypical antipsychotic use with nonuse, the matched pairs of community-dwelling older adults and long-term care residents repre- * The 95% CIs were estimated by using resampling methods (bootstrapping pairs of matched observations, with 1000 iterations).
Article Antipsychotic Drugs and Death among Patients with Dementia sented 96% and 48% of eligible atypical antipsychotic users, respectively. The lower match rate in the long-term care cohort reflects the smaller pool of nonusers available in this setting, because recently institutionalized people with dementia are frequently exposed to antipsychotics (4). In the comparison of conventional with atypical antipsychotic use, the matched pairs of community-dwelling older adults and longterm care residents represented 95% and 92% of eligible conventional antipsychotic users, respectively. To support the appropriateness of excluding patients for whom we could not find adequate matches, we examined the characteristics of unmatched atypical antipsychotic users. Compared with matched patients, unmatched patients were younger, were more likely to be male, were more likely to have had recent hospitalizations with delirium and investigations (such as computed tomography of the head), and had more physician and hospital visits. Those differences in the demographic profile and health services utilization of unmatched and matched atypical antipsychotic users were all statistically significant.
Atypical Antipsychotic Use versus Nonuse
Figure 1 plots cumulative mortality for atypical antipsychotic use and nonuse. Table 3 shows crude event rates and absolute risk differences for mortality at 30 and 180 days. The number of patients at risk decreased over time in an unequal manner. We were concerned that this might represent informative censoring. We therefore examined the characteristics of the remaining patients at 60 days and found that they stayed well balanced despite the unequal rates of censoring. New use of atypical antipsychotic medications was associated with a statistically significant increase in the risk for death at 30 days compared with nonuse in both the community-dwelling cohort (adjusted hazard ratio, (Tables 3 and 4) . Although the hazard ratios for mortality in the long-term care cohort were similar to those in the community-dwelling cohort, cumulative mortality was almost twice as high among longterm care residents (Figure 1) .
Conventional versus Atypical Antipsychotic Use
As shown in Figure 2 , use of conventional antipsychotics was associated with an even greater risk for death than that observed with atypical antipsychotic use. This risk was evident at 30 days: The adjusted hazard ratio was 1. 55 
Sensitivity Analyses
Sensitivity analyses for 30-day outcomes with atypical antipsychotic use compared with nonuse found that an unmeasured confounder that increased mortality could statistically significantly diminish the observed relationship between use of atypical antipsychotics and death ( Table 6) . For example, if the unmeasured confounder was associated with a moderate increase in mortality (bivariate hazard ratio, 1.5), the association between atypical antipsychotic use and death was no longer statistically significant regardless of the prevalence of the unmeasured confounder in the 2 groups. On the other hand, an unmeasured confounder would need to be more strongly associated with mortality to reduce the link between conventional antipsychotic use and death at 30 days in the comparison of conventional and atypical antipsychotic use ( Table 6 ). For example, the hazard ratio for death with conventional antipsychotic use loses statistical significance only when the unmeasured confounder has a bivariate hazard ratio of at least 2.0 and is very unevenly distributed (that is, 30% prevalence among atypical antipsychotic users and 60% prevalence among conventional antipsychotic users).
DISCUSSION
Our study provides further evidence that use of atypical antipsychotics is associated with a small but significant increase in mortality among older adults with dementia. In addition, the risk for death associated with antipsychotics is apparent after as little as 1 month of use and may persist for 6 months. Finally, these data provide independent confirmation of reports that use of conventional antipsychotics confers an even greater risk for death than does use of atypical antipsychotics (15, 18 ).
Our population-based, matched cohort study includes 5 times as many atypical antipsychotic users and nonusers as that in a meta-analysis of RCTs (14), includes many conventional antipsychotic users (a group for whom few data from RCTs exist), and provides follow-up data to 6 months. Our results complement and extend the findings of studies that examined the relationship between antipsychotic exposure and death in different patient samples Article Antipsychotic Drugs and Death among Patients with Dementia (14 -16, 18, 19, 32-37) . The meta-analysis by Schneider and colleagues (14) includes 15 RCTs that evaluated several atypical antipsychotics in the short-term management of neuropsychiatric symptoms of dementia. Our results are consistent with that meta-analysis and provide further insight in a nontrial population with longer follow-up and greater exposure to conventional antipsychotics. Wang and colleagues (15) used U.S. administrative data to compare the risk for death among new users of conventional and atypical antipsychotics. They used various sophisticated observational study techniques to address potential confounding factors. Similar to our results, Wang and colleagues (15) found that conventional antipsychotics were associated with a statistically significantly higher risk for death at all intervals up to 180 days after treatment initiation. In the first 180 days of use, the absolute event rates were dramatic: 17.9% of patients who began using conventional antipsychotics and 14.6% of patients who began using atypical antipsychotics died (15) .
The potential causes of death associated with antipsychotic use merit consideration. We did not have information on the proximate causes of death for all patients (38, 39) . Nonetheless, several plausible mechanisms can be proposed. First, antipsychotics may prolong the QT interval, predisposing patients to arrhythmias and sudden cardiac death (40 -46) . Second, sedation and accelerated cognitive decline brought on by exposure to antipsychotics may increase the risk for aspiration syndromes and choking (47) (48) (49) . Aspiration pneumonia is an important cause of death among people with dementia (38) . Third, several studies have found a link between atypical antipsychotic use and venous thromboembolism (50, 51) ; therefore, pulmonary embolism may be an underrecognized cause of sudden death in these patients. Fourth, a risk for cerebrovascular events may be associated with antipsychotic use, although this risk has been questioned (52, 53) . Finally, antipsychotics may contribute to events that are not initially recognized as the first step in a sequence that promotes premature death, such as falls leading to hip fractures (54) . Although details are limited, deaths in the RCTs seem to have been primarily related to cardiac arrhythmias and aspiration pneumonia (12) . A review of the RCTs that evaluated olanzapine supports these proposed mechanisms of harm (16) .
These results have important implications for clinical practice. First, conventional antipsychotics seem to be associated with a higher risk for death than are atypical antipsychotics (15, 18) . Second, the estimated mortality rate among study participants was high, especially in the longterm care setting (as one might expect among vulnerable older adults with dementia) (55) . Despite these high mortality rates, we can still detect excess mortality associated with exposure to antipsychotics. In the U.S. FDA and Health Canada reviews (12, 13) , the risk for death seemed to be a class effect with all atypical antipsychotics studied, and 2 meta-analyses confirmed these findings (14, 16) . Thus, switching between individual atypical antipsychotics in an attempt to modify the risk for death cannot be recommended. Finally, and perhaps most complex, the role of atypical antipsychotics in the management of behavioral and psychological symptoms of dementia must be carefully reviewed (56, 57) . Rabins and Lyketsos (17) suggest an approach that limits the use of these drugs to situations in which "there is an identifiable risk of harm to the patient or others, when the distress caused by symptoms is significant, or when alternate therapies have failed and symptom relief would be beneficial." Because the risk for death associated with antipsychotics develops quickly and may persist for up to 6 months, clinicians must reevaluate benefits and risks frequently and consider discontinuation of treatment when appropriate. Studies have shown that some patients receiving antipsychotics can be successfully weaned from these medications when monitored closely (58 -61) . Antipsychotic therapies should not be initiated if effective non- Our study has important limitations. First, we used administrative data and observational study techniques. Our risk estimates are relatively small and may therefore be confounded by other variables, and our ability to control for differences in the cohorts was limited to variables with available data. The sensitivity analyses highlight these limitations. Nevertheless, our results are consistent with findings from other research, including a meta-analysis of RCTs (14) . Second, we did not examine the risk for death posed by individual antipsychotic drugs. However, regulatory warnings and 2 meta-analyses have shown that the increased risk for death is consistent among the individual drugs in this class (12) (13) (14) 16) . Third, we could not examine the causes of death. Fourth, we did not examine doseresponse relationships, given the complexity of our study design and changes in dosages over time. Of note, no statistically significant relationship between antipsychotic dose and risk for death was found in the meta-analysis of olanzapine RCTs (16) . Fifth, we could not match all potentially eligible patients, which may limit the generalizability of our findings. Finally, we restricted our study to older adults with dementia. The safety of antipsychotics when used for other indications (for example, schizophrenia and delirium) requires further evaluation (36, 37, 67).
In conclusion, we show that older adults with dementia who are exposed to atypical antipsychotics have a small but significant increase in overall mortality that is evident as early as 1 month after initiation of treatment, and this risk may persist for 6 months. Use of conventional antipsychotics seems to confer an even greater risk for death than does atypical antipsychotic use. These findings highlight the need to carefully balance potential risks and benefits when considering antipsychotic treatment for older adults with dementia and emphasize the need to limit use of these drugs to situations in which nonpharmacologic measures have provided an inadequate response. * These analyses assume that the unmeasured confounder is binary, the unmeasured confounder is independent of measured confounders, there is no interaction between the unmeasured confounder and exposure, and the prevalence of the unmeasured confounder is greater in the exposed group than in the unexposed group. P 1 ϭ prevalence of the unmeasured confounder in the atypical antipsychotic group (in analysis 1) or the conventional antipsychotic group (in analysis 2); P 0 ϭ prevalence of the unmeasured confounder in the nonuse group (in analysis 1) or the atypical antipsychotic group (in analysis 2). † For the presence versus the absence of the unmeasured confounder (in either comparison group). ‡ For 30-day mortality. § Atypical antipsychotic users versus nonusers. The overall result (without adjustment for the unmeasured confounder) was a hazard ratio of 1.31 (CI, 1.02-1.70).
Conventional antipsychotic users versus atypical antipsychotic users. The overall result (without adjustment for the unmeasured confounder) was a hazard ratio of 1.55 (CI, 1.19 -2.02).
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